Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2024-03-19

Original market date: See footnote 1

2024-03-19

Product name:

BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP

Description:

SINGLE DOSE AMPOULE

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02536714

Product Monograph/Veterinary Labelling:

Date: 2023-03-27 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

FORMATIVE PHARMA INC.
200 4145 North Service Road
Burlington
Ontario
Canada L7L 6A3

Class:

Human

Dosage form(s):

Solution

Route(s) of administration:

Intraspinal

Number of active ingredient(s):

1

Schedule(s):

Ethical

 

American Hospital Formulary Service (AHFS): See footnote 3

72:00.00 

Anatomical Therapeutic Chemical (ATC): See footnote 4

N01BB01 BUPIVACAINE

Active ingredient group (AIG) number:See footnote5

0108896002

List of active ingredient(s)
Active ingredient(s) See footnote8 Strength
BUPIVACAINE HYDROCHLORIDE 7.5 MG / ML
Version 4.0.3

"Page details"

Date modified: